19-去さ甲かぶと睾酮

**19-去さ甲かぶと睾酮**
臨床りんしょう資料しりょう
读音	/ˈnændrəloʊn/
商品しょうひん名めい（英えい语：Drug nomenclature）	• Deca-Durabolin (as ND); • Durabolin (as NPP); • Many others (see here)
其他名稱めいしょう	• 19-Nortestosterone; • 10-Nortestosterone; • Estr-4-en-17βべーた-ol-3-one; • Estrenolone / Oestrenolone; • 19-Norandrost-4-en-17βべーた-ol-3-one; • Norandrostenolone; • Nortestrionate / Nortestonate; • SG-4341
懷ふところ孕分級きゅう	澳: D ; ;
给药途と径みち	• Intramuscular injection (esters); • Eye drops (as NS)
藥物やくぶつ類別るいべつ（英えい语：Drug class）	Androgen; Anabolic steroid; Progestogen
ATC碼	A14AB01 (WHO) S01XA11;
法律ほうりつ規範きはん狀態じょうたい
法律ほうりつ規範きはん	加か：Schedule IV; 英えい：Class C; 美よし：附ふ表ひょうIII;
藥物やくぶつ動力どうりょく學がく數かず據よりどころ
生物せいぶつ利用りよう度ど	• Oral: <3% (pigs); • Intramuscular: high
药物代だい谢	Liver (reduction)
代謝たいしゃ產物さんぶつ	• 5αあるふぁ-Dihydronandrolone; • 19-Norandrosterone; • 19-Noretiocholanolone; • Conjugates
生物せいぶつ半はん衰おとろえ期き	• Nandrolone: <4.3 hours; • ND (IM): 6–12 days; • NPP: 2.7 days
作用さよう時間じかん	• ND (IM): 2–3 weeks; • NPP (IM): 5–7 days
排泄はいせつ途と徑みち	Urine
识别信しん息いき
	IUPAC命名めいめい法ほう (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; ;
CAS号ごう	434-22-0
PubChem CID	9904;
IUPHAR/BPS	6949;
ChemSpider	9520 ;
UNII	6PG9VR430D;
ChEBI	CHEBI:7466 ;
ChEMBL	ChEMBL757 ;
CompTox Dashboard（英えい语：CompTox Chemicals Dashboard） (EPA)	DTXSID7023350 ;
ECHA InfoCard	100.006.457
化学かがく信しん息いき
化学かがく式しき	C18H26O2
摩ま尔质量りょう	274.404 g/mol
3D模型もけい（JSmol（英えい语：JSmol））	交互こうご式しき图像;
	SMILES O=C4\C=C2/[C@@H]([C@H]1CC[C@@]3([C@@H](O)CC[C@H]3[C@@H]1CC2)C)CC4;
	InChI InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1 ; Key:NPAGDVCDWIYMMC-IZPLOLCNSA-N ;

19-去さ甲かぶと睾酮（英語えいご：19-nortestosterone）也被称しょう为诺龙（Nandrolone）是ぜ一いち种雄お激げき素もと和わ同化どうか類るい固かた醇あつし（AAS）。其酯类衍生物ぶつ（如其苯丙酸さん酯、癸みずのと酸さん酯等ひとし^[2]^[10]^[6]^[11]）常つね作さく为贫血、惡病あくびょう體質たいしつ、骨質こっしつ疏鬆症しょう、乳癌にゅうがん的てき治ち疗药物ぶつ^[6]，不能ふのう通どおり过口くち服ふく给药，只ただ能のう进行肌はだ肉にく注射ちゅうしゃ给药^[6]^[11]。

由よし于19-去さ甲かぶと睾酮是ぜ雄ゆう激げき素もと睾酮的てき去さ甲きのえ基はじめ化か类似物ぶつ，因いん此它能のう作さく为睾酮和双そう氢睾酮（DHT）的てき生物せいぶつ学がく靶点——雄お激げき素もと受体（AR）的てき激げき动剂^[6]^[12]，在ざい人体じんたい内ない引起一いち些雄ゆう性せい化か症狀しょうじょう，如痤疮、毛もう发增长、声音こわね嘶哑、性欲せいよく增强ぞうきょう等ひとし副作用ふくさよう^[6]。相そう比ひ较而言げん，19-去さ甲かぶと睾酮的てき一いち些酯化か产物蛋白たんぱく同化どうか活性かっせい较强，而雄お激げき素もと活性かっせい较弱，可か以作为适用よう于妇女おんな儿童的てき较温和おんわ药物^[6]^[12]^[13]，以及具有ぐゆう缓释作用さよう的てき前ぜん体からだ药物^[6]。

参考さんこう文献ぶんけん

^ Nandrolone Meaning in the Cambridge English Dictionary. [2019-02-15]. （原始げんし内容ないよう存そん档于2015-02-09）.
^ ^2.0 ^2.1 J. Elks. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014: 660–. ISBN 978-1-4757-2085-3.
^ McEvoy JD, McVeigh CE, McCaughey WJ. Residues of nortestosterone esters at injection sites. Part 1. Oral bioavailability. Analyst. 1998, 123 (12): 2475–8. PMID 10435281. doi:10.1039/a804919j.
^ Kenneth L. Becker. Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. 2001: 1185– [2019-02-15]. ISBN 978-0-7817-1750-2. （原始げんし内容ないよう存そん档于2020-05-17）.
^ ^5.0 ^5.1 ^5.2 ^5.3 ^5.4 ^5.5 ^5.6 存そん档副本ふくほん (PDF). [2019-02-15]. （原始げんし内容ないよう存そん档 (PDF)于2020-11-11）.
^ ^6.00 ^6.01 ^6.02 ^6.03 ^6.04 ^6.05 ^6.06 ^6.07 ^6.08 ^6.09 ^6.10 William Llewellyn. Anabolics. Molecular Nutrition Llc. 2011: 402–412, 460–467, 193–194. ISBN 978-0-9828280-1-4.
^ ^7.0 ^7.1 John A. Thomas. Drugs, Athletes, and Physical Performance. Springer Science & Business Media. 6 December 2012: 27–29. ISBN 978-1-4684-5499-4.
^ ^8.0 ^8.1 ^8.2 Minto CF, Howe C, Wishart S, Conway AJ, Handelsman DJ. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J. Pharmacol. Exp. Ther. 1997, 281 (1): 93–102. PMID 9103484.
^ 存そん档副本ふくほん (PDF). [2019-02-15]. （原始げんし内容ないよう存そん档 (PDF)于2019-03-09）.
^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000: 716–. ISBN 978-3-88763-075-1.
^ ^11.0 ^11.1 Walter Sneader. Drug Discovery: A History. John Wiley & Sons. 23 June 2005: 206–. ISBN 978-0-471-89979-2.
^ ^12.0 ^12.1 Kicman AT. Pharmacology of anabolic steroids. Br. J. Pharmacol. 2008, 154 (3): 502–21. PMC 2439524 . PMID 18500378. doi:10.1038/bjp.2008.165.
^ Charles D. Kochakian. Anabolic-Androgenic Steroids. Springer Science & Business Media. 6 December 2012: 401– [2019-02-17]. ISBN 978-3-642-66353-6. （原始げんし内容ないよう存そん档于2019-09-09）.

延伸えんしん阅读

Geusens P. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Clin. Rheumatol. 1995,. 14 Suppl 3: 32–9. PMID 8846659. doi:10.1007/bf02210686.
Kicman AT. Pharmacology of anabolic steroids. Br. J. Pharmacol. 2008, 154 (3): 502–21. PMC 2439524 . PMID 18500378. doi:10.1038/bjp.2008.165.
Hemmersbach P, Grosse J. Nandrolone: a multi-faceted doping agent. Handbook of Experimental Pharmacology 195. 2010: 127–54. ISBN 978-3-540-79087-7. PMID 20020363. doi:10.1007/978-3-540-79088-4_6. |journal=被ひ忽ゆるがせ略りゃく (帮助); |issue=被ひ忽ゆるがせ略りゃく (帮助)
Velema MS, Kwa BH, de Ronde W. Should androgenic anabolic steroids be considered in the treatment regime of selected chronic obstructive pulmonary disease patients?. Curr Opin Pulm Med. 2012, 18 (2): 118–24. PMID 22189453. doi:10.1097/MCP.0b013e32834e9001.
Busardò FP, Frati P, Sanzo MD, Napoletano S, Pinchi E, Zaami S, Fineschi V. The impact of nandrolone decanoate on the central nervous system. Curr Neuropharmacol. 2015, 13 (1): 122–31. PMC 4462037 . PMID 26074747. doi:10.2174/1570159X13666141210225822.
Wu C, Kovac JR. Novel Uses for the Anabolic Androgenic Steroids Nandrolone and Oxandrolone in the Management of Male Health. Curr Urol Rep. 2016, 17 (10): 72. PMID 27535042. doi:10.1007/s11934-016-0629-8.
Pan MM, Kovac JR. Beyond testosterone cypionate: evidence behind the use of nandrolone in male health and wellness. Transl Androl Urol. 2016, 5 (2): 213–9. PMC 4837307 . PMID 27141449. doi:10.21037/tau.2016.03.03.

[1] Nandrolone Meaning in the Cambridge English Dictionary. [2019-02-15]. （原始げんし内容ないよう存そん档于2015-02-09）.

[Elks2014-2] 2.0 ^2.1 J. Elks. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014: 660–. ISBN 978-1-4757-2085-3.

[pmid10435281-3] McEvoy JD, McVeigh CE, McCaughey WJ. Residues of nortestosterone esters at injection sites. Part 1. Oral bioavailability. Analyst. 1998, 123 (12): 2475–8. PMID 10435281. doi:10.1039/a804919j.

[Becker2001-4] Kenneth L. Becker. Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. 2001: 1185– [2019-02-15]. ISBN 978-0-7817-1750-2. （原始げんし内容ないよう存そん档于2020-05-17）.

[Label-NZ-5] 5.0 ^5.1 ^5.2 ^5.3 ^5.4 ^5.5 ^5.6 存そん档副本ふくほん (PDF). [2019-02-15]. （原始げんし内容ないよう存そん档 (PDF)于2020-11-11）.

[Llewellyn2011-6] 6.00 ^6.01 ^6.02 ^6.03 ^6.04 ^6.05 ^6.06 ^6.07 ^6.08 ^6.09 ^6.10 William Llewellyn. Anabolics. Molecular Nutrition Llc. 2011: 402–412, 460–467, 193–194. ISBN 978-0-9828280-1-4.

[Thomas2012-7] 7.0 ^7.1 John A. Thomas. Drugs, Athletes, and Physical Performance. Springer Science & Business Media. 6 December 2012: 27–29. ISBN 978-1-4684-5499-4.

[pmid9103484-8] 8.0 ^8.1 ^8.2 Minto CF, Howe C, Wishart S, Conway AJ, Handelsman DJ. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J. Pharmacol. Exp. Ther. 1997, 281 (1): 93–102. PMID 9103484.

[Label-AU-9] 存そん档副本ふくほん (PDF). [2019-02-15]. （原始げんし内容ないよう存そん档 (PDF)于2019-03-09）.

[IndexNominum2000-10] Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000: 716–. ISBN 978-3-88763-075-1.

[Sneader2005-11] 11.0 ^11.1 Walter Sneader. Drug Discovery: A History. John Wiley & Sons. 23 June 2005: 206–. ISBN 978-0-471-89979-2.

[pmid18500378-12] 12.0 ^12.1 Kicman AT. Pharmacology of anabolic steroids. Br. J. Pharmacol. 2008, 154 (3): 502–21. PMC 2439524 . PMID 18500378. doi:10.1038/bjp.2008.165.

[Kochakian2012-13] Charles D. Kochakian. Anabolic-Androgenic Steroids. Springer Science & Business Media. 6 December 2012: 401– [2019-02-17]. ISBN 978-3-642-66353-6. （原始げんし内容ないよう存そん档于2019-09-09）.

[1]

[2]

[3]

[4]

[5]

[7]

[6]

[8]

[9]

[10]

[11]

[12]

[13]